Cycling Versus Swapping After First-Line TNF Inhibitor Failure in Psoriatic Arthritis: Real-World Insights From the Argentine RECCAPSO Registry

Objectives: Cycling within the same mechanism of action (MoA) or swapping to a different MoA are 2 strategies after failure of advanced therapy in psoriatic arthritis (PsA). We described the frequency, clinical characteristics, and treatment trajectory of cycling versus swapping at the first switch in a multicenter Argentine PsA cohort. Methods: Retrospective cohort analysis of 350 consecutive adults with PsA fulfilling CASPAR criteria and enrolled in the RECCAPSO registry. Among 179 patients with documented first-line treatment lineage, the comparative analysis was restricted to those who discontinued first-line TNFi because of primary inefficacy or secondary loss of response. Cycling was defined as switching to another TNFi and swapping as switching to a different MoA. Between-group comparisons were exploratory and performed using Mann-Whitney U and Fisher exact tests. Results: Of 350 patients, 183 (52%) received advanced therapy; 60/179 (33.5%) experienced first-line failure, all while receiving TNFi. Of these, 18 (30%) cycled and 42 (70%) swapped. The median interval from first-line to second-line initiation was 18 months [interquartile range (IQR): 4 to 60] in cyclers and 19 months (IQR: 6 to 56) in swappers. At the first switch, swappers had higher C-reactive protein (3.4 vs. 1.6 mg/L; P =0.04) and numerically less enthesitis (38.1% vs. 66.7%; P =0.08). At the subsequent cross-sectional assessment during second-line therapy, DAPSA remission was observed in 18.4% of swappers and 0% of cyclers ( P =0.09). Third-line therapy was initiated in 77.8% of cyclers and 31.0% of swappers ( P =0.0015); among those reaching a third line, the median interval from second-line to third-line initiation was 5 months (IQR: 2 to 9) and 13 months (IQR: 4 to 34), respectively. Conclusions: Swapping was the predominant strategy after first-line TNFi failure. Cyclers more frequently initiated a third line and, among those who escalated, did so earlier.

Authors

Institutions

Publication Details

Journal
JCR Journal of Clinical Rheumatology
Published
2026-10-07
DOI
https://doi.org/10.1097/rhu.0000000000002408
Primary Topic
Spondyloarthritis Studies and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Cycling Versus Swapping After First-Line TNF Inhibitor Failure in Psoriatic Arthritis: Real-World Insights From the Argentine RECCAPSO Registry

Leila Abbas, G. Medina, Sebastian Magri, Maximiliano Fenucci et al.
JCR Journal of Clinical Rheumatology
Spondyloarthritis Studies and Treatments
article

Cycling Versus Swapping After First-Line TNF Inhibitor Failure in Psoriatic Arthritis: Real-World Insights From the Argentine RECCAPSO Registry

Leila Abbas, G. Medina, Sebastian Magri, Maximiliano Fenucci, Rodrigo Garcia-Salinas, Marcelo Abdala, Brian Abdala
article en

Abstract

Objectives: Cycling within the same mechanism of action (MoA) or swapping to a different MoA are 2 strategies after failure of advanced therapy in psoriatic arthritis (PsA). We described the frequency, clinical characteristics, and treatment trajectory of cycling versus swapping at the first switch in a multicenter Argentine PsA cohort. Methods: Retrospective cohort analysis of 350 consecutive adults with PsA fulfilling CASPAR criteria and enrolled in the RECCAPSO registry. Among 179 patients with documented first-line treatment lineage, the comparative analysis was restricted to those who discontinued first-line TNFi because of primary inefficacy or secondary loss of response. Cycling was defined as switching to another TNFi and swapping as switching to a different MoA. Between-group comparisons were exploratory and performed using Mann-Whitney U and Fisher exact tests. Results: Of 350 patients, 183 (52%) received advanced therapy; 60/179 (33.5%) experienced first-line failure, all while receiving TNFi. Of these, 18 (30%) cycled and 42 (70%) swapped. The median interval from first-line to second-line initiation was 18 months [interquartile range (IQR): 4 to 60] in cyclers and 19 months (IQR: 6 to 56) in swappers. At the first switch, swappers had higher C-reactive protein (3.4 vs. 1.6 mg/L; P =0.04) and numerically less enthesitis (38.1% vs. 66.7%; P =0.08). At the subsequent cross-sectional assessment during second-line therapy, DAPSA remission was observed in 18.4% of swappers and 0% of cyclers ( P =0.09). Third-line therapy was initiated in 77.8% of cyclers and 31.0% of swappers ( P =0.0015); among those reaching a third line, the median interval from second-line to third-line initiation was 5 months (IQR: 2 to 9) and 13 months (IQR: 4 to 34), respectively. Conclusions: Swapping was the predominant strategy after first-line TNFi failure. Cyclers more frequently initiated a third line and, among those who escalated, did so earlier.

JCR Journal of Clinical Rheumatology
Universidad de Buenos Aires (AR), National University of Rosario (AR), Hospital Provincial de Rosario (AR), Hospital Italiano La Plata (AR), Hospital de Clínicas "José de San Martín" (AR), Hospital de Clínicas (UY), Hospital César Milstein (AR)
Openalex Percentile: Top 12%
Spondyloarthritis Studies and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.